Presentations
J.P. Morgan Healthcare Conference Presentation
Jan 10, 2022
CVL-231: Results From an Early Proof-Of-Concept Study in Patients With Schizophrenia
Dec 08, 2021
Evaluation of M4 Muscarinic Receptor Occupancy by CVL-231 in Nonhuman Primates
Dec 08, 2021
Cerevel Therapeutics Corporate Presentation
Nov 10, 2021
Cerevel Therapeutics R&D Day Presentation
Oct 07, 2021
Cerevel Therapeutics Corporate Presentation
Aug 11, 2021
Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia Presentation
Jun 29, 2021
Cerevel Therapeutics Corporate Presentation
May 17, 2021
$125M Non-Dilutive Financing for Tavapadon Presentation
Apr 13, 2021
Virtual R&D Event: Darigabat, PDE4, KORA
Jan 28, 2021
View PDF 4.4 MB